slides · global inventory
Resolution
Beat collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 42,534
Current window 24,031-24,060
Pages 1,418
Rows per page 30
Beat
24,031-24,060 of 42,534
11
3M | Results Presentation Deck | 16 slides3M | Results Presentation Deck | 16 slides · 3M
Conference presentation Investor relations Beat · New Bliss1 hit
12
The table displays financial results in millions of dollars, comparing year-over-year performance.3M | Results Presentation Deck | 16 slides · 3M
Conference presentation Investor relations Beat · New Bliss1 hit
13
The slide presents a breakdown of organic volume, price, acquisitions/divestitures, and FX impacts on total growth.3M | Results Presentation Deck | 16 slides · 3M
Conference presentation Investor relations Beat · New Bliss1 hit
14
Data includes adjustments for corporate and unallocated items. Organic local-currency is defined as organic volume + price.3M | Results Presentation Deck | 16 slides · 3M
Conference presentation Investor relations Beat · New Bliss1 hit
15
Financial data table showing 3M business group performance.3M | Results Presentation Deck | 16 slides · 3M
Conference presentation Investor relations Beat · New Bliss1 hit
16
3M | Results Presentation Deck | 16 slides3M | Results Presentation Deck | 16 slides · 3M
Conference presentation Investor relations Beat · New Bliss1 hit
46
argenx SE | Investor Day Presentation Deck | 69 slidesargenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
47
Branded Argenx presentation slide.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
48
argenx SE | Investor Day Presentation Deck | 69 slidesargenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
49
Includes names of presenters and company logo.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
50
The diagram shows the classical, lectin, and alternative pathways converging at C3 convertase, with C2 highlighted as a target.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
51
The slide uses a process flow diagram to illustrate the complement system and justifies targeting C2 over other components.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
52
The slide uses a process flow diagram to explain the mechanism of action for a potential therapeutic intervention.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
53
The slide uses a biological pathway diagram to justify a therapeutic target.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
54
The slide uses a process flow diagram to justify targeting C2. It contrasts this with other potential targets (labeled 1 and 2) and highlights the benefits of C2 inhibition.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
55
The slide uses a circular process diagram to explain the biological mechanism of the drug.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
56
The slide uses a timeline-like structure to show dose escalation cohorts for IV and SC administration.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
57
The slide presents clinical trial safety data for ARGX-117, highlighting that most adverse events are low grade and unrelated to the drug.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
58
SAD = Single Ascending Dose. PD = Pharmacodynamic.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
59
The slide shows two line charts comparing different dosing regimens over time.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
60
The chart compares three dosing regimens (60mg/kg LD + 10mg/kg Q2W, 40mg/kg Q4W, 60mg/kg Q8W) against a 99% reduction threshold.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
61
argenx SE | Investor Day Presentation Deck | 69 slidesargenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
62
The slide highlights the clinical burden and market opportunity for new therapies.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
63
The slide uses a numbered list format to explain a biological mechanism and clinical correlation.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
64
The slide uses immunofluorescence microscopy to demonstrate the efficacy of ARGX-117 in preventing complement-mediated damage.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
65
The slide uses a visual gradient to represent dose-dependency in a biological assay.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
66
The slide uses a before-after comparison to demonstrate the efficacy of ARGX-117 in preserving neurofilaments.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
67
The slide uses a process flow diagram to illustrate the clinical trial stages.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
68
The diagram uses a Venn-like structure nested within a larger circle to show the relationship between biological pathways, therapeutic franchises, and specific disease indications.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
69
The slide features a list of 11 individuals with their professional titles and affiliations.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Impact & Next Steps1 hit